Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (108)	9/10/2009 8:50:09 AM
From: John McCarthy	Respond to of 421

Hi Ken * playing this out for the RUSH ... its that simple (so I've let all the money stay on what I see are the 6 and 8) * this company has the toolset to go after solid tumors but their poor * they need a 20+ people phase 2 for pancreatic to wake people up ... (they have figured out the dosing) * I hope this goes to $10 and they immediately go out with a 2 million++ offering - if they can get away with it - not certain ... * Its not clear to me why they chose pancreatic over liver but perhaps it was a cost issue (London vs Singapore) EDIT Forgot the most important part - that was an outstanding analysis you wrote yesterday. Thank you. regards John